DK2257624T5 - Fremgangsmåder og sammensætninger - Google Patents

Fremgangsmåder og sammensætninger

Info

Publication number
DK2257624T5
DK2257624T5 DK09708496.6T DK09708496T DK2257624T5 DK 2257624 T5 DK2257624 T5 DK 2257624T5 DK 09708496 T DK09708496 T DK 09708496T DK 2257624 T5 DK2257624 T5 DK 2257624T5
Authority
DK
Denmark
Prior art keywords
polypeptide
methods
compositions
relates
attached
Prior art date
Application number
DK09708496.6T
Other languages
English (en)
Other versions
DK2257624T3 (da
Inventor
Gregory Winter
Christian Heinis
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40792924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2257624(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0802079.4A external-priority patent/GB0802079D0/en
Priority claimed from GB0818399A external-priority patent/GB0818399D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of DK2257624T3 publication Critical patent/DK2257624T3/da
Application granted granted Critical
Publication of DK2257624T5 publication Critical patent/DK2257624T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
DK09708496.6T 2008-02-05 2009-02-04 Fremgangsmåder og sammensætninger DK2257624T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0802079.4A GB0802079D0 (en) 2008-02-05 2008-02-05 Method and compositions
GB0818399A GB0818399D0 (en) 2008-10-08 2008-10-08 Methods and compositions
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions

Publications (2)

Publication Number Publication Date
DK2257624T3 DK2257624T3 (da) 2012-05-29
DK2257624T5 true DK2257624T5 (da) 2012-09-10

Family

ID=40792924

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09708496.6T DK2257624T5 (da) 2008-02-05 2009-02-04 Fremgangsmåder og sammensætninger
DK12151953.2T DK2474613T3 (da) 2008-02-05 2009-02-04 Fremgangsmåder og sammensætninger

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12151953.2T DK2474613T3 (da) 2008-02-05 2009-02-04 Fremgangsmåder og sammensætninger

Country Status (11)

Country Link
US (3) US8680022B2 (da)
EP (5) EP2653543A1 (da)
JP (2) JP6074574B2 (da)
AT (1) ATE555200T1 (da)
AU (1) AU2009211253B2 (da)
CA (1) CA2714477C (da)
DK (2) DK2257624T5 (da)
ES (2) ES2509959T5 (da)
PL (1) PL2257624T3 (da)
PT (1) PT2257624E (da)
WO (1) WO2009098450A2 (da)

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
EP2603586B2 (en) 2010-08-13 2025-02-26 Miti Biosystems GmbH Modified peptide display
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
MY180616A (en) 2011-06-30 2020-12-03 Genzyme Corp Inhibitors of t-cell activation
AU2012320407B2 (en) * 2011-10-07 2017-04-20 Bicyclerd Limited Modulation of structured polypeptide specificity
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
EP2810069A4 (en) 2012-02-03 2015-08-12 Univ Alberta METHOD FOR THE QUANTIFICATION OF PEPTIDE DERIVATIVE LIBRARIES BY PHAG DISPLAY
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
HK1207970A1 (en) 2012-05-10 2016-02-19 Massachusetts Institute Of Technology Agents for influenza neutralization
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
ES2732574T3 (es) * 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
CN105683211B (zh) * 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
EP3137482A1 (en) 2014-05-02 2017-03-08 MorphoSys AG Peptide libraries
GB201413086D0 (en) 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
AU2015336857B2 (en) 2014-10-22 2020-04-09 The Governors Of The University Of Alberta Genetic encoding of chemical post-translational modification for phage-displayed libraries
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
KR101693665B1 (ko) * 2014-11-13 2017-01-06 목포해양대학교 산학협력단 설치와 철거가 용이한 구조를 가지는 기초의 세굴방지장치 및 이를 이용한 기초의 세굴방지방법
MA41022A (fr) 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
JP6609099B2 (ja) * 2014-12-10 2019-11-20 キヤノン株式会社 放射線検出装置、及び放射線検出シート
DK3237614T3 (da) 2014-12-22 2019-09-09 Lanthiopep Bv Nye fremgangsmåder til fremvisning af cyklisk peptider på overfladen af bakteriofagpartikler
EP3286314B1 (en) * 2015-04-23 2019-06-26 H. Hoffnabb-La Roche Ag Cow antibody scaffold polypeptide method and composition
JP2015214568A (ja) * 2015-07-13 2015-12-03 バイスクル・セラピューティクス・リミテッド 多重特異性ペプチド
CA3014921A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
DK3467107T3 (da) * 2016-06-07 2022-06-27 Kaneka Corp Ribosomdisplaykompleks og fremstillingsfremgangsmåde dertil
CN110114075B (zh) 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
US11352394B2 (en) 2016-11-22 2022-06-07 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
US10913773B2 (en) 2016-11-22 2021-02-09 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US10441663B2 (en) 2016-11-27 2019-10-15 Bicyclerd Limited Methods for treating cancer
CA3046171A1 (en) 2016-12-06 2018-06-14 Stichting Voor De Technische Wetenschappen Multicyclic peptides and methods for their preparation
JP7387440B2 (ja) * 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
WO2018115203A1 (en) * 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
WO2018134265A1 (en) 2017-01-17 2018-07-26 Forrest Michael David Therapeutic inhibitors of the reverse mode of atp synthase
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CA3064512A1 (en) 2017-06-09 2018-12-13 Vib Vzw Glutamine dehydrogenase inhibitors for use in muscle regeneration
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
EP4036234A1 (en) 2017-07-17 2022-08-03 Vib Vzw Screening method for synaptogyrin-3 inhibitors
CN111183147B (zh) * 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
US20210132072A1 (en) 2017-10-26 2021-05-06 Vib Vzw Podoplanin positive macrophages
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810329D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
US12391939B2 (en) * 2018-07-23 2025-08-19 The Governors Of The University Of Alberta Genetically-encoded bicyclic peptide libraries
US11655468B2 (en) 2018-07-25 2023-05-23 The Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020023620A1 (en) * 2018-07-25 2020-01-30 Trustees Of Boston College Methods and compositions of chemically modified phage libraries
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201819659D0 (en) 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
CA3122669A1 (en) 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
JP2022514618A (ja) * 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3935069A1 (en) 2019-03-04 2022-01-12 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP7660555B2 (ja) 2019-08-07 2025-04-11 ギロス プロテイン テクノロジーズ エービー トレースレスな還元的切断可能なリンカー分子により固体支持体へ固定化されるペプチドを修飾するための方法
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
ES3033517T3 (en) * 2019-10-03 2025-08-05 Bicycletx Ltd Heterotandem bicyclic peptide complexes
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
CN110907422B (zh) * 2019-12-16 2021-07-06 吉林大学 基于Ti3C2的凝血酶适体传感器及其制备方法
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
WO2021123767A1 (en) 2019-12-16 2021-06-24 Bicycletx Limited Bicyclic peptide ligands specific for il-17
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
CN115768456A (zh) 2020-04-06 2023-03-07 拜斯科技术开发有限公司 Tslp特异性的双环肽配体
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
WO2021229238A1 (en) 2020-05-15 2021-11-18 Bicycletx Limited Anti-infective bicyclic peptide ligands
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
CN111893577B (zh) * 2020-08-06 2022-03-22 厦门大学 基于4-羟基-2,6-二氟-1,3,5-苯三腈构建噬菌体展示环肽库的方法
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4216943A1 (en) 2020-09-24 2023-08-02 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
IL302713A (en) 2020-11-13 2023-07-01 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
AU2022206394A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
AU2022205795A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Anti-infective bicyclic peptide ligands
CN117157305A (zh) 2021-01-08 2023-12-01 拜斯科技术开发有限公司 抗感染的双环肽配体
WO2022148970A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CA3206846A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
KR20230141794A (ko) 2021-01-08 2023-10-10 바이사이클티엑스 리미티드 헤테로탠덤 바이사이클릭 펩티드 복합체
US20240083944A1 (en) 2021-01-08 2024-03-14 Bicycle TX Limited Anti-infective bicyclic peptide ligands
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
EP4308586A1 (en) 2021-03-19 2024-01-24 BicycleTX Limited Bicyclic peptide ligands specific for trem2
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
CN117203219A (zh) 2021-04-20 2023-12-08 拜斯科技术开发有限公司 特异性针对p-选择素的双环肽配体
WO2023012343A1 (en) 2021-08-06 2023-02-09 Institut Du Cancer De Montpellier Methods for the treatment of cancer
AU2022340959A1 (en) 2021-09-03 2024-03-07 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
MX2024004011A (es) 2021-10-01 2024-07-01 Adarx Pharmaceuticals Inc Composiciones moduladoras de precalicreína y métodos de uso de estas.
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
GB202116263D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Anti-infective bicyclic peptide ligands
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
GB202206431D0 (en) 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
EP4658281A1 (en) 2023-01-30 2025-12-10 Vib Vzw Suppressors of tauopathies
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
AU2023449926A1 (en) 2023-06-01 2026-01-08 Bicycletx Limited Bicyclic peptide ligands specific for epha2 and uses thereof
WO2024248859A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024246547A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2024246551A1 (en) 2023-06-01 2024-12-05 Bicycletx Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
KR20260038313A (ko) 2023-06-07 2026-03-18 페프티드림 아이엔씨. 글리피칸-3을 표적화하는 펩티드 조성물 및 그의 용도
CN121532408A (zh) 2023-06-23 2026-02-13 拜斯科技术开发有限公司 对nk细胞具有特异性的双环肽配体
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
WO2025046244A1 (en) 2023-09-01 2025-03-06 Bicycletx Limited Tlr3 binding bicyclic peptide ligands
AU2024342769A1 (en) 2023-09-13 2026-04-23 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025067347A1 (zh) * 2023-09-28 2025-04-03 深圳湾实验室坪山生物医药研发转化中心 噬菌体颗粒复合物、其制备方法及其用途
WO2025085724A1 (en) * 2023-10-18 2025-04-24 University Of Utah Research Foundation An enzymatic method for synthesis of interpeptide thioether crosslinks
GB202316970D0 (en) 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
WO2025125809A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide ligands specific for nectin-4 and uses thereof
WO2025125648A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Bicyclic peptide complex for use in treating cancer
WO2025191096A1 (en) 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
GB202410566D0 (en) 2024-07-19 2024-09-04 Bicycletx Ltd Computer implemented method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
ES2327382T3 (es) * 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
WO2001023619A1 (en) * 1999-09-29 2001-04-05 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
WO2002077182A2 (en) 2001-03-21 2002-10-03 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
AU2003225085A1 (en) 2002-04-19 2003-11-03 California Institute Of Technology Unnatural amino acid containing display libraries
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
DK1844337T3 (da) * 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
EP1855723B1 (en) 2005-03-08 2013-05-22 Ramot at Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
CA2659225A1 (en) * 2006-07-26 2008-01-31 Pepscan Systems B.V. Immunogenic compounds and protein mimics
AU2007336132A1 (en) * 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular CCR5 peptide conjugates and uses thereof

Also Published As

Publication number Publication date
ATE555200T1 (de) 2012-05-15
EP2653545A1 (en) 2013-10-23
US20100317547A1 (en) 2010-12-16
EP2653544A1 (en) 2013-10-23
ES2509959T5 (en) 2024-12-19
US20140187757A1 (en) 2014-07-03
JP6075658B2 (ja) 2017-02-08
DK2257624T3 (da) 2012-05-29
US8680022B2 (en) 2014-03-25
US9657288B2 (en) 2017-05-23
CA2714477A1 (en) 2009-08-13
EP2474613B1 (en) 2014-07-16
JP2011514803A (ja) 2011-05-12
PT2257624E (pt) 2012-05-29
WO2009098450A2 (en) 2009-08-13
PL2257624T3 (pl) 2012-09-28
JP2015109856A (ja) 2015-06-18
EP2474613A1 (en) 2012-07-11
CA2714477C (en) 2018-10-16
EP2474613B2 (en) 2022-02-16
AU2009211253B2 (en) 2014-11-06
WO2009098450A3 (en) 2009-10-29
AU2009211253A1 (en) 2009-08-13
EP2257624A2 (en) 2010-12-08
ES2509959T3 (es) 2014-10-20
ES2383191T3 (es) 2012-06-19
EP2257624B9 (en) 2012-08-01
EP2653543A1 (en) 2013-10-23
US9670484B2 (en) 2017-06-06
US20150166988A1 (en) 2015-06-18
EP2257624B1 (en) 2012-04-25
ES2383191T9 (es) 2012-10-16
DK2474613T3 (da) 2014-10-06
JP6074574B2 (ja) 2017-02-08

Similar Documents

Publication Publication Date Title
DK2257624T3 (da) Fremgangsmåder og sammensætninger
EA201170168A1 (ru) Комплекс (минерал-аминокислота)-полисахарид
MX2009007695A (es) Compuestos complejos de carbohidrato de hierro.
NZ603495A (en) Algorithm for designing irreversible inhibitors
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
CY1113056T1 (el) Παρασκευη ανασυνδυασμενης συνδετικης πρωτεϊνης il-18
EP4345163A3 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
CY1110010T1 (el) Πυριδιναμινοσουλφονυλ υποκατεστημενα βενζαμιδια ως αναστολεις κυτοχρωματος ρ450 3α4 (cyp3a4)
MX2008012627A (es) Metodos para producir materiales de estructura metalica-organica conteniendo metales del subgrupo iv.
WO2011060242A3 (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
MX2010002463A (es) Plantas con rasgos relacionados con un rendimiento aumentado y un metodo para producirlas.
GB2453808B (en) Novel compounds from antrodia camphorata
WO2012059873A3 (en) Anti-diabetic compounds
WO2009097626A3 (en) Paired-end reads in sequencing by synthesis
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
IL265947A (en) Preparation of stansoporfin with a high degree of purification on a large scale
DE602006020881D1 (de) Enen eigenschaften
CY1110944T1 (el) Νεα παραγωγα κυκλοαλκυλιωμενων βενζοθειαδιαζινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
TW200631939A (en) Process for cross coupling indoles
EA201170606A1 (ru) Феназопиридиновые соединения
ATE424439T1 (de) Radikalisch härtbare beschichtungsmassen
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
WO2008075966A3 (en) Synthesis of a radiofluorinated peptide using photolabile protecting groups